Q1 Earnings Estimate for DRTS Issued By HC Wainwright

Alpha Tau Medical Ltd. (NASDAQ:DRTS - Free Report) - Research analysts at HC Wainwright issued their Q1 2026 EPS estimates for Alpha Tau Medical in a research note issued on Thursday, May 22nd. HC Wainwright analyst Y. Chen anticipates that the company will post earnings per share of ($0.12) for the quarter. HC Wainwright currently has a "Buy" rating and a $9.00 price objective on the stock. The consensus estimate for Alpha Tau Medical's current full-year earnings is ($0.45) per share. HC Wainwright also issued estimates for Alpha Tau Medical's FY2026 earnings at ($0.46) EPS.

Alpha Tau Medical (NASDAQ:DRTS - Get Free Report) last posted its quarterly earnings data on Monday, May 19th. The company reported ($0.12) EPS for the quarter, topping analysts' consensus estimates of ($0.14) by $0.02.

Alpha Tau Medical Trading Down 1.0%

NASDAQ DRTS traded down $0.03 during trading on Monday, hitting $2.97. 960 shares of the company traded hands, compared to its average volume of 71,371. The company has a market capitalization of $208.96 million, a P/E ratio of -6.90 and a beta of 0.92. The business has a fifty day simple moving average of $2.70 and a 200 day simple moving average of $2.94. Alpha Tau Medical has a 12 month low of $1.75 and a 12 month high of $4.39.

Institutional Trading of Alpha Tau Medical

Several institutional investors have recently modified their holdings of the company. Renaissance Technologies LLC grew its stake in Alpha Tau Medical by 188.7% during the fourth quarter. Renaissance Technologies LLC now owns 41,000 shares of the company's stock worth $127,000 after buying an additional 26,800 shares during the last quarter. Levin Capital Strategies L.P. grew its stake in shares of Alpha Tau Medical by 2.3% during the fourth quarter. Levin Capital Strategies L.P. now owns 314,514 shares of the company's stock worth $975,000 after purchasing an additional 7,189 shares during the period. Kovitz Investment Group Partners LLC increased its stake in shares of Alpha Tau Medical by 601.4% in the 1st quarter. Kovitz Investment Group Partners LLC now owns 226,320 shares of the company's stock valued at $568,000 after acquiring an additional 194,055 shares during the last quarter. XTX Topco Ltd bought a new stake in Alpha Tau Medical in the first quarter valued at approximately $53,000. Finally, Northern Trust Corp raised its stake in Alpha Tau Medical by 112.6% during the 4th quarter. Northern Trust Corp now owns 48,666 shares of the company's stock worth $151,000 after buying an additional 25,770 shares during the period. Institutional investors and hedge funds own 2.65% of the company's stock.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.